无转移生存与生化复发前列腺癌无治疗生存：EMBARK 试验。
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
机构信息
Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
Harvard Medical School, Boston, MA.
出版信息
J Clin Oncol. 2024 Aug 20;42(24):2849-2852. doi: 10.1200/JCO.24.00279. Epub 2024 May 16.
Abstract
What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.
摘要
对于患有 BCR 前列腺癌的患者来说，最重要的是什么？无转移生存与无治疗生存。
相似文献
1
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.无转移生存与生化复发前列腺癌无治疗生存：EMBARK 试验。
J Clin Oncol. 2024 Aug 20;42(24):2849-2852. doi: 10.1200/JCO.24.00279. Epub 2024 May 16.
2
Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.吸烟与生化疾病复发、转移、去势抵抗性前列腺癌以及根治性前列腺切除术后的死亡率增加相关：来自 SEARCH 数据库的结果。
Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Epub 2013 Oct 11.
3
Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.前列腺癌初次根治性前列腺切除术或放疗后去势抵抗的差异风险
Anticancer Res. 2017 Oct;37(10):5631-5637. doi: 10.21873/anticanres.11998.
4
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
5
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.在新型疗法背景下，有生化复发前列腺癌的男性雄激素剥夺治疗时机。
J Urol. 2021 Sep;206(3):623-629. doi: 10.1097/JU.0000000000001797. Epub 2021 May 18.
6
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.恩杂鲁胺治疗去势抵抗性前列腺癌非转移性患者的疗效。
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
7
Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?治疗后游离前列腺特异性抗原比值能否用于预测复发性前列腺癌的不良结局？
BJU Int. 2021 Jun;127(6):654-664. doi: 10.1111/bju.15236. Epub 2020 Sep 26.
8
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.醋酸阿比特龙联合泼尼松治疗非转移性生化复发的去势敏感前列腺癌。
Eur J Cancer. 2021 Nov;157:259-267. doi: 10.1016/j.ejca.2021.06.017. Epub 2021 Sep 15.
9
Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.预测局限性前列腺癌根治术后生化复发后进展为去势抵抗性前列腺癌的因素。
Int J Clin Oncol. 2020 Sep;25(9):1704-1710. doi: 10.1007/s10147-020-01716-8. Epub 2020 Jun 4.
10
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.醋酸阿比特龙治疗化疗后进展的转移性去势抵抗性前列腺癌患者：多中心、开放标签、早期准入方案试验的最终分析。
Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.
引用本文的文献
1
The role of radiotherapy in pelvic nodal recurrence following definitive treatment for prostate cancer.放射治疗在前列腺癌根治性治疗后盆腔淋巴结复发中的作用。
Curr Opin Urol. 2025 Sep 1;35(5):574-582. doi: 10.1097/MOU.0000000000001322. Epub 2025 Jul 17.
2
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.常规影像学检查无转移疾病的高危生化复发前列腺癌患者的PSMA-PET/CT表现
JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971.
本文引用的文献
1
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.EMBARK 和 PSMA PET 成像时代的生化复发前列腺癌：一切都变了，除了患者。
Curr Opin Oncol. 2024 May 1;36(3):164-168. doi: 10.1097/CCO.0000000000001030. Epub 2024 Feb 23.
2
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗生化复发前列腺癌的疗效改善。
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
3
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.寡转移前列腺癌转移灶定向治疗与观察的长期结局和反应的遗传预测：STOMP 和 ORIOLE 试验分析。
J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24.
4
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.免疫检查点抑制剂治疗与晚期肾细胞癌靶向治疗后的无治疗生存：CheckMate 214 试验的 42 个月结果。
Clin Cancer Res. 2021 Dec 15;27(24):6687-6695. doi: 10.1158/1078-0432.CCR-21-2283. Epub 2021 Nov 10.
5
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.前列腺癌患者中地加瑞克与亮丙瑞林的心血管安全性：PRONOUNCE 随机试验的主要结果。
Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30.
6
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.转移性去势敏感性前列腺癌患者接受恩杂鲁胺和雄激素剥夺治疗的总生存情况。
Eur Urol. 2021 Sep;80(3):275-279. doi: 10.1016/j.eururo.2021.05.016. Epub 2021 May 22.
7
Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.在新型疗法背景下，有生化复发前列腺癌的男性雄激素剥夺治疗时机。
J Urol. 2021 Sep;206(3):623-629. doi: 10.1097/JU.0000000000001797. Epub 2021 May 18.
8
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.口服瑞戈非尼在晚期前列腺癌中的雄激素剥夺治疗。
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
9
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.转移性去势抵抗性前列腺癌中恩扎卢胺和醋酸阿比特龙联合泼尼松序贯治疗的最佳顺序：一项多中心、随机、开放标签、2 期、交叉试验。
Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11.
10
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.无治疗生存：免疫检查点抑制作用的新型疗效评估指标——晚期黑色素瘤患者的汇总分析
J Clin Oncol. 2019 Dec 10;37(35):3350-3358. doi: 10.1200/JCO.19.00345. Epub 2019 Sep 9.
Zotero 插件